Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment
- 25 February 2013
- journal article
- review article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 36 (3), 127-135
- https://doi.org/10.1159/000348524
Abstract
Background: Cytotoxic extravasation is a rare but potentially serious and painful complication of intravenous drug administration in oncology. Literature is anecdotal, and systematic clinical trials are scarce. The German working group for Supportive Care in Cancer (ASORS) has prepared an expert opinion for the diagnosis, prophylaxis and management of cytotoxic extravasation based on an interdisciplinary expert panel. Material and Methods: A Pubmed search was conducted for diagnosis, risk factors, symptoms, prophylaxis, and treatment of extravasation by the respective responsible expert. A writing committee compiled the manuscript and proposed the level of recommendation. In a consensus meeting, 13 experts reviewed and discussed the current practice in diagnosis and management of cytotoxic extravasation. In a telephone voting among the experts, the level of recommendation by ASORS was determined. Results: Every effort should be made to reduce the risk of extravasation. Staff training, patient education, usage of right materials and infusion techniques have been identified to be mandatory to minimalize the risk of extravasation. Extravasation must be diagnosed as soon as possible, and specific therapy including antidotes dependent on the extravasated drug should be initiated immediately. An extravasation emergency set should be available wherever intravenous cytotoxics are applied. Documentation and post-treatment follow-up are recommended. Conclusion: We have developed a literature- and expert-based consensus recommendation to avoid cytotoxic extravasation. It also provides practical management instructions which should help to avoid surgery and serious late effects.Keywords
This publication has 42 references indexed in Scilit:
- Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue DamageJournal of Clinical Oncology, 2009
- Dexrazoxane Treatment for Intrathoracic Anthracycline ExtravasationOncology Research and Treatment, 2008
- Bendamustine: A Novel Cytotoxic Agent for Hematologic MalignanciesClinical Journal of Oncology Nursing, 2008
- Managing Vesicant ExtravasationsThe Oncologist, 2008
- Venous Access Ports: Frequency and Management of Complications in Oncology PatientsOnkologie, 2008
- Paravasation with Cyclophosphamide – Case Report of Tissue Necrosis in a Patient with Primary Breast CancerOncology Research and Treatment, 2007
- Cutaneous Recall Phenomenon at the Site of Previous Doxorubicin Extravasation After Second-Line ChemotherapyJNCI Journal of the National Cancer Institute, 2007
- Extravasations of OxaliplatinJournal of Clinical Oncology, 2003
- "Clinicopathologic and Prognostic Significance of an Angiogenic Factor, Thymidine Phosphorylase, in Human Colorectal Carcinoma"JNCI Journal of the National Cancer Institute, 1996
- Skin ulceration potential of paclitaxel in a mouse skin model in vivoCancer, 1996